Journal of Psychoactive Drugs
October 23, 2024
Jessica L Maples-Keller, Courtland S Hyatt, Nathaniel L Phillips et al.
2 citations
3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research suggests a change in personality traits may be a factor in treatment response. Most prior research on MDMA and personality has focused on cross-sectional comparisons of MDMA users and non-users; as such, well-controlled research assessing personality and...
Journal of Psychopharmacology
February 15, 2022
Jessica L Maples-Keller, Seth D. Norrholm, Mark Burton et al.
53 citations
Background: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. Aims: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. Methods:...
FOCUS: The Journal of Lifelong Learning in Psychiatry
2021
Collin Reiff, Elon E. Richman, Charles B. Nemeroff et al.
17 citations
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in...
Journal of Affective Disorders
August 15, 2018
Patricio Riva-Posse, Collin Reiff, Johnathan A Edwards et al.
The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication. There are many questions about the potential risks of this treatment and hence the proper setting and degree of monitoring required to ensure patient safety. There is limited data about the cardiovascular safety of...
Frontiers in Psychiatry
August 25, 2017
J. Douglas Bremner, Sanskriti Mishra, Carolina Campanella et al.
81 citations
OBJECTIVE: Brain imaging studies in patients with post-traumatic stress disorder (PTSD) have implicated a circuitry of brain regions including the medial prefrontal cortex, amygdala, hippocampus, parietal cortex, and insula. Pharmacological treatment studies have shown a reversal of medial prefrontal deficits in response to traumatic reminders. Mindfulness-based stress reduction (MBSR) is a...
Psychopharmacology
July 24, 2017
Matthew B Young, Seth D. Norrholm, Lara M. Khoury et al.
103 citations
We validate enhancement of fear memory extinction by MDMA in a translational behavioral model, and reveal the importance of 5-HTT and 5-HT2A receptors to this effect. These observations support future clinical research of MDMA as an adjunct to exposure therapy, and provide important pharmacological considerations for clinical use in a population frequently treated with 5-HTT inhibitors.